Amylyx Pharmaceuticals Inc
AMLX7.860USD
+0.145+1.88%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
700.18MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Amylyx Pharmaceuticals Inc Unternehmen
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Unternehmensinformationen
BörsenkürzelAMLX
Name des UnternehmensAmylyx Pharmaceuticals Inc
IPO-datumJan 07, 2022
CEOMr. Justin Klee
Anzahl der mitarbeiter123
WertpapierartOrdinary Share
GeschäftsjahresendeJan 07
Addresse43 Thorndike Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02141
Telefon16176820917
Websitehttps://www.amylyx.com/
BörsenkürzelAMLX
IPO-datumJan 07, 2022
CEOMr. Justin Klee
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
87.37M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 25
Aktualisiert: Fri, Jul 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
37.33%
Investment Advisor
25.77%
Individual Investor
9.53%
Private Equity
9.22%
Investment Advisor/Hedge Fund
6.10%
Research Firm
3.54%
Venture Capital
2.72%
Pension Fund
0.22%
Sovereign Wealth Fund
0.13%
Other
5.44%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
402
86.90M
97.48%
-7.80M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
2023Q1
276
73.14M
110.85%
-1.57M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Perceptive Advisors LLC
7.87M
8.83%
+1.10M
+16.24%
Mar 31, 2025
TCG Crossover Management, LLC
5.94M
6.67%
+1.30M
+27.99%
Mar 31, 2025
Adage Capital Management, L.P.
5.70M
6.39%
+5.70M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.12M
4.62%
+1.42M
+52.89%
Mar 31, 2025
Klee (Justin B)
3.36M
3.76%
+235.72K
+7.56%
Apr 11, 2025
Cohen (Joshua Barry)
3.36M
3.76%
+299.42K
+9.80%
Apr 11, 2025
Millennium Management LLC
3.08M
3.46%
+2.49M
+418.62%
Mar 31, 2025
Nantahala Capital Management, LLC
2.93M
3.29%
+1.48M
+102.07%
Mar 31, 2025
Citadel Advisors LLC
2.76M
3.09%
+787.07K
+39.94%
Mar 31, 2025
Saturn V Capital Management LP
2.43M
2.72%
+1.54M
+172.92%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.22%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.44%
Federated Hermes MDT Small Cap Core ETF
Anteil0.22%
iShares Micro-Cap ETF
Anteil0.1%
Invesco Nasdaq Biotechnology ETF
Anteil0.06%
ProShares Ultra Nasdaq Biotechnology
Anteil0.06%
Avantis US Small Cap Equity ETF
Anteil0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
